THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era. Wednesday, March 11, 2026

COMPOUND WATCH

BPC-157 [Animal → Phase 2] — The compound you've been injecting blind just entered its first registered human trial (NCT07437547). Acute hamstring strain. Recruiting now. This is the most significant development in BPC-157's history — not because it proves anything, but because it means someone is finally trying to prove something. Evidence grade upgrades from [Animal] to [Phase 2 Recruiting]. The Croatian rat data that's been driving your 250-500 mcg SC dosing protocol? Still the only efficacy signal you have. But the angiogenesis/cancer concern that's been floating in Telegram channels? A properly run trial will generate the first human safety data. Watch the adverse event reporting.

Tirzepatide [Phase 3/FDA-approved] — Eli Lilly moved again this week to expand direct access. The compounding window is closing: FDA pulled semaglutide from shortage, tirzepatide is next in line for the same treatment. If you're sourcing compounded tira at $50-149/vial from a U.S. vendor vs. $4.80/vial from QSC [Unverified], that spread is about to get more relevant as 503A/503B options narrow.

Retatrutide [Phase 3] — Three simultaneous Phase 3 trials recruiting right now (obesity maintenance, CLBP, and the core obesity study). 28.7% weight loss at 68 weeks. FDA approval projected 2027-2028. The gray market will have "retatrutide" vials before the ink dries on approval — start thinking now about what verification looks like for a compound with no established reference standard in the community testing ecosystem.

VENDOR SIGNAL

QSC (Qingdao Sigma Chemical) [COA Only] — Still the dominant direct-China option. 350+ Janoshik tests on record, which is more than any U.S. research vendor ever posted before shutdown. Tirzepatide at $4.80/vial vs. the compounding pharmacy equivalent at $200-500/month is not a close call on price. It is a close call on endotoxin. Verify any specific lot at public.janoshik.com before you inject — the aggregate test record is strong, but individual lot variance is real. Contact "Tracy" via Telegram. Crypto only.

Peptide Sciences [Flagged] — Shut down February 2026. $7.45M in December 2025 sales and then gone. If you have a supplier you found through a Peptide Sciences recommendation thread, re-verify independently. Community trust doesn't transfer.

Amino Asylum [Flagged] — FDA raid, June 2025. Do not source from any entity claiming to be a successor operation without independent Finnrick verification. Check finnrick.com for current ratings before any order.

No new Finnrick rating changes surfaced today. If you're deciding between vendors right now, finnrick.com is the live source — don't rely on a Reddit thread from two months ago.

TRIAL TRACKER

NCT07437547 — BPC-157, Phase 2, Recruiting (Start: Feb 2026) First human RCT for BPC-157, period. Hamstring strain population. This doesn't validate your gut-healing protocol — but it generates the first human safety and pharmacokinetic data the community has ever had. Watch for enrollment updates.

NCT07357415 — Retatrutide Phase 3, Recruiting (Start: Jan 2026) Obesity/overweight, no T2D. This is the pivotal trial that gets retatrutide to your pharmacy — or to QSC's catalog first. 28.7% weight loss is the number that ends the semaglutide conversation.

NCT07437547 companion note — Survodutide LIVERAGE Phase 3, Recruiting GLP-1/glucagon dual agonist targeting MASH/liver fibrosis. If you're on a GLP-1 and have elevated liver enzymes, this trial's existence tells you the mechanism is real. Not gray-market available yet — but it will be.

THE ODDS

US Recession by End of 2026: 30% ($479,253 volume traded)

At 30%, this is noise for your monthly peptide budget — uncomfortable but not decision-changing. Watch the threshold at 40%. That's where discretionary $300/month compounding spend starts getting cut, gray-market China sourcing accelerates (lower price point, higher tolerance for verification gaps), and compounders who are already margin-squeezed by the GLP-1 shortage ruling start shedding non-GLP-1 compound lines.

The Hims-Novo deal (March 9) matters here: if the telehealth-to-brand-distributor model becomes the template, recession pressure plus regulatory squeeze means the middle of the market (503A compounders, U.S. research vendors) gets hollowed out. You'll be left choosing between brand pricing and direct-China. Plan accordingly.

SIGNAL VS. NOISE

SIGNAL: BPC-157 Phase 2 trial recruiting (NCT07437547) Zero human RCTs to first human RCT is not a small step. The evidence grade changes. The safety conversation changes. If you're currently running BPC-157, this trial's adverse event data — when it publishes — is the first thing that should update your risk calculus.

SIGNAL: Novo Nordisk REDEFINE 4 trial triggered a 16% stock plunge A Phase 3 miss on a major obesity indication moves markets and shifts pipeline priorities. When Novo bleeds, compounding demand for semaglutide alternatives doesn't disappear — it redirects. Tirzepatide and retatrutide pipelines benefit.

SIGNAL: Sex-specific GLP-1 brain atlas published New research shows GLP-1 receptors are distributed differently in female vs. male brains, which may explain differential weight loss response and side effect profiles. [Phase 3 adjacent — mechanism research] If you're dosing a partner differently and getting different results, this is why. Not anecdote. Biology.

NOISE: RFK Jr.'s Category 2 → Category 1 reclassification promise Still no Federal Register notice. Still no formal FDA rule. Enforcement discretion is not legal protection. BPC-157, TB-500, CJC-1295, Ipamorelin — none of them are officially reclassified as of today. Anyone telling you the ban is lifted is selling you something.

NOISE: "Oral GLP-1 is here" content flooding your feed Orforglipron is real and Phase 3 data is compelling. But FDA decision is expected March 2026 — not confirmed. And Tiximed's oral TIX-100 preventing weight regain post-GLP-1 cessation is preclinical data only [Animal]. The oral revolution is coming. It is not here today.

REGULATORY RADAR

Hims & Hers / Novo Nordisk (March 9, 2026): Hims ceased compounded semaglutide. Now distributes branded Ozempic/Wegovy. HIMS stock +50%. Read this clearly: the largest telehealth platform just exited the compounding business. This is the model the FDA and brand manufacturers want to replicate. If you're sourcing compounded sema through any telehealth platform, your window is narrowing — not closing today, but the direction is unambiguous.

FDA Warning: Novo Nordisk / Unreported GLP-1 Side Effect — FDA issued a warning to Novo this week for failing to report a potential adverse event associated with semaglutide. The irony: the most-regulated compound in this space still has reporting gaps. Keep that in mind when someone tells you the gray-market stuff is the dangerous one. Risk exists on both ends of the supply chain.

February 2026 Warning Letter Wave: 30 telehealth companies received FDA warning letters last month. If your telehealth provider hasn't communicated clearly about their compounding status, call them. The ones going quiet are the ones restructuring.

Tailor Made Compounding: Guilty plea, $1.79M forfeiture. Criminal prosecutions are not theoretical. They are ongoing. This is what happens at the far end of the enforcement spectrum — not a warning letter, a courtroom.

WHAT TO WATCH

This week: Orforglipron FDA decision window — first oral non-peptide GLP-1. Approval reshapes the entire access conversation.

Ongoing: BPC-157 Phase 2 enrollment pace (NCT07437547) — first human data timeline depends on how fast they recruit.

Ongoing: Any Federal Register notice on Category 2 → Category 1 reclassification. RFK Jr. said it on Rogan. It has not happened in writing. Those are different things.

March/April: FDA approval decisions calendar — check thecardiologyadvisor.com for the running list. Peptide-adjacent mechanisms are moving fast.

The number to watch: Retatrutide Phase 3 interim data. 28.7% weight loss is the ceiling we know about. The maintenance trial (NCT06858268) will tell us if the weight stays off.

If you do one thing today: Verify your current vendor's most recent lot on public.janoshik.com. Not the COA they sent you. The public database. Those are sometimes different documents.

Reply to this email with what you're running, what you're questioning, or what you want covered. The best issues come from your questions.

Stay curious, stay skeptical. — The Dose